141 related articles for article (PubMed ID: 21733929)
21. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.
Klepzig M; Sauer-Eppel H; Jonas D; Oremek GM
Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432
[TBL] [Abstract][Full Text] [Related]
22. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
23. Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference.
Tridimas A; Milan A; Marks E
Ann Clin Biochem; 2021 Sep; 58(5):528-536. PubMed ID: 34096326
[TBL] [Abstract][Full Text] [Related]
24. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
25. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
26. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
[TBL] [Abstract][Full Text] [Related]
27. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
28. Effect of age-related chronic immobility on markers of bone turnover.
Chen JS; Cameron ID; Cumming RG; Lord SR; March LM; Sambrook PN; Simpson JM; Seibel MJ
J Bone Miner Res; 2006 Feb; 21(2):324-31. PubMed ID: 16418789
[TBL] [Abstract][Full Text] [Related]
29. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
30. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
31. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
32. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
33. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J
Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402
[TBL] [Abstract][Full Text] [Related]
34. Bone metabolism markers and ghrelin in boys at different stages of sexual maturity.
Jürimäe J; Pomerants T; Tillmann V; Jürimäe T
Acta Paediatr; 2009 May; 98(5):892-6. PubMed ID: 19243352
[TBL] [Abstract][Full Text] [Related]
35. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
36. Serum markers of bone metabolism in dogs.
Allen MJ; Hoffmann WE; Richardson DC; Breur GJ
Am J Vet Res; 1998 Mar; 59(3):250-4. PubMed ID: 9522938
[TBL] [Abstract][Full Text] [Related]
37. [Serum PINP(N-terminal propeptide of type I procollagen)].
Ueda M; Inaba M
Nihon Rinsho; 2004 Feb; 62 Suppl 2():373-7. PubMed ID: 15035155
[No Abstract] [Full Text] [Related]
38. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis].
Nakatsuka K; Nishizawa Y; Miura M
Clin Calcium; 2006 Jun; 16(6):977-85. PubMed ID: 16751694
[TBL] [Abstract][Full Text] [Related]
39. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
Ylisirniö S; Sassi ML; Risteli J; Turpeenniemi-Hujanen T; Jukkola A
Anticancer Res; 1999; 19(6C):5577-81. PubMed ID: 10697621
[TBL] [Abstract][Full Text] [Related]
40. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Morko J; Rasi S; Risteli J; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):155-61. PubMed ID: 18219436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
